Cambridge-based Ironwood Pharmaceuticals and partner Almirall said today that European regulators have approved a drug to treat irritable bowel syndrome with constipation in adults.
The drug would be marketed in Europe as Constella, an oral, once-daily medication. Ironwood received U.S. Food and Drug Administration approval for linaclotide in August.
Almirall, which signed a license agreement with Ironwood in April 2009, under which the company holds exclusive marketing rights for linaclotide in all European Union member states, expects to launch Constella in Europe in the first half of next year.
"We look forward to continuing to work closely with our partner Almirall in their efforts to bring Constella to ... patients in Europe, and we will continue collaborating with our global network of partners with the goal of bringing this medicine to appropriate patients worldwide," said Ironwood's CEO Peter Hecht.
Anda sedang membaca artikel tentang
Ironwood drug wins approval in Europe
Dengan url
http://wartegjokowi.blogspot.com/2012/11/ironwood-drug-wins-approval-in-europe.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Ironwood drug wins approval in Europe
namun jangan lupa untuk meletakkan link
Ironwood drug wins approval in Europe
sebagai sumbernya
0 komentar:
Posting Komentar